Current Oncology Reports

, Volume 11, Issue 5, pp 337–345 | Cite as

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?

Article

Abstract

Imatinib mesylate, 400 mg/d, is considered standard therapy for managing patients with chronic myeloid leukemia (CML) in chronic phase, yielding high rates of cytogenetic responses that translate into favorable long-term outcomes. However, some patients do not achieve adequate levels of response, lose a previously acquired response, or are forced to discontinue imatinib therapy because of safety reasons. To avoid these outcomes, several approaches are being tested in the frontline setting, including the use of higher imatinib doses or second-generation tyrosine kinase inhibitors such as nilotinib or dasatinib, the latter of which is approved only for managing patients who have imatinib therapy failure. Newer multikinase inhibitors active against multiple ABL1 mutations are also under development for patients in any CML phase who have therapy failure on sequential imatinib and a second-generation tyrosine kinase inhibitor or carry the highly resistant T315I mutation and are not candidates for allogeneic stem cell transplantation. Some of these approaches are expected to improve the outcomes of patients with CML.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.PubMedCrossRefGoogle Scholar
  2. 2.
    O’Brien SG, Guilhot F, Goldman J, et al.: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 2008, 112:186.Google Scholar
  3. 3.
    O’Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423–1432.PubMedCrossRefGoogle Scholar
  5. 5.
    Cortes J, Talpaz M, O’Brien S, et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425–3432.PubMedCrossRefGoogle Scholar
  6. 6.
    de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intentionto-treat analysis. J Clin Oncol 2008, 26:3358–3363.PubMedCrossRefGoogle Scholar
  7. 7.
    Quintás-Cardama A, Kantarjian HM, Cortes JE: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122–131.PubMedGoogle Scholar
  8. 8.
    Weisberg E, Manley PW, Cowan-Jacob SW, et al.: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345–356.PubMedCrossRefGoogle Scholar
  9. 9.
    Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022–4028.PubMedCrossRefGoogle Scholar
  10. 10.
    Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496–3499.PubMedCrossRefGoogle Scholar
  11. 11.
    Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.PubMedCrossRefGoogle Scholar
  12. 12.
    Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401–2409.PubMedCrossRefGoogle Scholar
  13. 13.
    Kantarjian H, O’Brien S, Shan J, et al.: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008, 112:837–845.PubMedCrossRefGoogle Scholar
  14. 14.
    Quintás-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia. New Engl J Med 2007, 357:1557; author reply 1558.PubMedGoogle Scholar
  15. 15.
    Kantarjian H, Talpaz M, O’Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873–2878.PubMedCrossRefGoogle Scholar
  16. 16.
    Cortes J, Giles F, O’Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003, 102:83–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008, 112:3965–3973.PubMedCrossRefGoogle Scholar
  18. 18.
    Cortes J, Baccarani M, Guilhot F, et al.: A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 2008, 112:335.Google Scholar
  19. 19.
    Baccarani M, Castagnetti F, Simonsson B, et al.: Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 2008, 112:185.Google Scholar
  20. 20.
    Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154–2160.PubMedCrossRefGoogle Scholar
  21. 21.
    Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658–6661.PubMedCrossRefGoogle Scholar
  22. 22.
    Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399–401.PubMedCrossRefGoogle Scholar
  23. 23.
    O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.PubMedCrossRefGoogle Scholar
  24. 24.
    Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531–2541.PubMedCrossRefGoogle Scholar
  25. 25.
    Mauro M, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7009.Google Scholar
  26. 26.
    Rousselot P, Facon T, Paquette R, et al.: Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standarddose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7012.Google Scholar
  27. 27.
    Shah N, Kim DW, Kantarjian H, et al.: Dasatinib doseoptimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood 2008, 112:3225.Google Scholar
  28. 28.
    Kantarjian H, Kim DW, Dorlhiac-Llacer P, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with accelerated phase chronic myeloid leukemia: 2-year follow-up data from CA180-035 [abstract]. Blood 2008, 112:3224.Google Scholar
  29. 29.
    Saglio G, Kantarjian H, Hochhaus A, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with chronic myeloid leukemia in blast phase: 2-year data from CA180-035 [abstract]. Blood 2008, 112:3226.Google Scholar
  30. 30.
    Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129–141.PubMedCrossRefGoogle Scholar
  31. 31.
    Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542–2551.PubMedCrossRefGoogle Scholar
  32. 32.
    Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3238.Google Scholar
  33. 33.
    Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540–3546.PubMedCrossRefGoogle Scholar
  34. 34.
    Le Coutre P, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3229.Google Scholar
  35. 35.
    Giles F, Larson RA, Kantarjian K, et al.: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. Blood 2007, 110:1025.CrossRefGoogle Scholar
  36. 36.
    Remsing Rix LL, Rix U, Colinge J, et al.: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23:477–485.PubMedCrossRefGoogle Scholar
  37. 37.
    Redaelli S, Piazza R, Rostagno R, et al.: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27:469–471.PubMedCrossRefGoogle Scholar
  38. 38.
    Cortes J, Kantarjian H, Kim DW, et al.: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 2008, 112:1098.Google Scholar
  39. 39.
    Gambacorti-Passerini C, Pogliani E, Baccarani M, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2008, 112:1101.CrossRefGoogle Scholar
  40. 40.
    Rosti G, Castagnetti F, Poerio A, et al.: High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 2008, 112:181.Google Scholar
  41. 41.
    Cortes J, O’Brien S, Borthakur G, et al.: Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CMLCP) [abstract]. Blood 2008, 112:182.Google Scholar
  42. 42.
    Cortes J, O’Brien S, Jones D, et al.: Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 2008, 112:446.Google Scholar
  43. 43.
    Quintás-Cardama A, Kantarjian H, Jones D, et al.: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497–499.PubMedCrossRefGoogle Scholar
  44. 44.
    Giles F, Le Coutre P, Bhalla K, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. Blood 2008, 112:3234.CrossRefGoogle Scholar
  45. 45.
    Garg RJ, Kantarjian H, O’Brien SM, et al.: The use of 2nd generation tyrosine kinase inhibitors (TKI) after failure to 2 prior TKI: long-term follow-up [abstract]. Blood 2008, 112:2119.Google Scholar
  46. 46.
    Kozopas KM, Yang T, Buchan HL, et al.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993, 90:3516–3520.PubMedCrossRefGoogle Scholar
  47. 47.
    Chen Y, Hu Y, Michaels S, et al.: Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 2007, 110:2912.Google Scholar
  48. 48.
    Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al.: Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, 109:248–255.PubMedCrossRefGoogle Scholar
  49. 49.
    Cortes J, Khoury HJ, Corm S, et al.: Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation—results of an ongoing multicenter phase II study [abstract]. Blood 2008, 112:3239.Google Scholar
  50. 50.
    Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 2008, 112:3232.Google Scholar
  51. 51.
    Paquette R, Shah N, Sawyers C, et al.: PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood 2007, 110:1030.Google Scholar
  52. 52.
    O’Hare T, Eide CA, Adrian LT, et al.: Complete suppression of in vitro resistance by AP24534, a pan-BCR-ABL inhibitor [abstract]. Blood 2008, 112:726.Google Scholar
  53. 53.
    Van Etten RA, Chan WW, Zaleskas VM, et al.: Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 2008, 112:576.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of LeukemiaUniversity of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations